title: Nuclear factor kappa B activation in human cord blood mononuclear cells.
abstract: The immunologic signals participating in immune responses early in life have not been completely elucidated. Regarding the characterization of neonatal cells, little is known concerning the activity of transcription factor nuclear factor kappa B (NF-kappaB), which regulates inflammatory genes and cytokine production. The aim of this study was to characterize NF-kappaB activation in cord blood mononuclear cells (CBMC). We analyzed the potential association of NF-kappaB activity with lymphocyte proliferation and influences on cytokine secretion in the early immune system. To determine the contribution of a disease whereby inheritance may impact neonatal immunity, we assessed the influence of maternal allergic disease on NF-kappaB regulation and cytokine secretion. CBMC from healthy newborns were isolated and stimulated with mitogen (n = 28). Nuclear extracts were analyzed by electrophoretic mobility shift assay, cytokine secretion by ELISA. FISH analysis excluded relevant maternal contamination of CBMC. All samples showed a positive lymphoproliferative response, and NF-kappaB activity was both increased and decreased after mitogen stimulation. Increased NF-kappaB activation was significantly associated with decreased TNF-alpha secretion (median 6.1 versus 50.3 pg/mL) in unstimulated CBMC. Mitogen stimulation resulted in increased NF-kappaB activity with a trend to increased IL-13 production. Maternal allergic disease was associated with higher TNF-alpha (median 982 versus 173 pg/mL) and IL-13 secretion (median 1328 versus 1120 pg/mL) after mitogen stimulation. Together, NF-kappaB activity is differentially activated in cord blood and associated with a distinct cytokine pattern. Whether differential NF-kappaB activity in cord blood is related to the subsequent development of immune diseases requires further investigation.
authors.affiliation: Pulmonary and Critical Care Division, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, U.S.A.
authors.forename: Christian H
authors.initials: CH
authors.lastname: Schroeter
authors.forename: Bianca
authors.initials: B
authors.lastname: Schaub
authors.forename: Diane R
authors.initials: DR
authors.lastname: Gold
authors.forename: Paola J
authors.initials: PJ
authors.lastname: Contreras
authors.forename: Oscar
authors.initials: O
authors.lastname: Manrique
authors.forename: Matthew W
authors.initials: MW
authors.lastname: Gillman
authors.forename: Scott
authors.initials: S
authors.lastname: Weiss
authors.forename: Lyle J
authors.initials: LJ
authors.lastname: Palmer
authors.forename: David
authors.initials: D
authors.lastname: Perkins
authors.forename: Patricia W
authors.initials: PW
authors.lastname: Finn
mesh_terms: D000328:Adult; D049109:Cell Proliferation; D002478:Cells, Cultured; D016207:Cytokines / Q000378:metabolism; D005260:Female; D005312:Fetal Blood / Q000166:cytology*; D006801:Humans; D007154:Immune System Diseases / Q000276:immunology; D007223:Infant; D007231:Infant, Newborn; D018793:Interleukin-13 / Q000276:immunology; D007963:Leukocytes, Mononuclear / Q000166:cytology / Q000187:drug effects / Q000276:immunology*; D008213:Lymphocyte Activation; D008297:Male; D016328:NF-kappa B / Q000378:metabolism*; D010835:Phytohemagglutinins / Q000276:immunology / Q000494:pharmacology; D011247:Pregnancy; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology
chemical_list: D016207:Cytokines; D018793:Interleukin-13; D016328:NF-kappa B; D010835:Phytohemagglutinins; D014409:Tumor Necrosis Factor-alpha